Skip to main content

Table 1 Clinical, laboratory and cardio-pulmonary features of patients with idiopathic inflammatory myopathies

From: TLR expression in peripheral monocyte subsets of patients with idiopathic inflammatory myopathies: association with clinical and immunological features

Variable Median (min–max)
Disease activity and damage
 Manual muscle test 8 (MMT8) 144 (45–150)
 Visual analogue scale of physician’s disease activity 5 (0–10)
 Visual analogue scale of patient’s disease activity 5 (0–10)
 Cutaneous dermatomyositis disease area and severity index (CDASI) acute 4 (0–76)
 Cutaneous dermatomyositis disease area and severity index (CDASI) chronic 2 (0–21)
 Visual analogue scale of constitutional disease activity 0 (0–10)
 Visual analogue scale of cutaneous disease activity 0 (0–10)
 Visual analogue scale of pulmonary disease activity 0 (0–10)
 Visual analogue scale of cardiovascular disease activity 0 (0–10)
 Visual analogue scale of other disease activity 0 (0–10)
 Visual analogue scale of extramuscular disease activity 3 (0–10)
 Visual analogue scale of muscular disease activity 0 (0–10)
 Visual analogue scale of global disease activity 5 (0–10)
 Total myositis disease activity assessment visual analogue scales (MYOACT) 1.4 (0–7.5)
 Total myositis intention to treat activity index (MITAX) 0.85 (0–5.71)
 Visual analogue scale of muscular damage 0 (0–10)
 Visual analogue scale of skeletal damage 0 (0–9)
 Visual analogue scale of cutaneous damage 1 (0–10)
 Visual analogue scale of gastrointestinal damage 0 (0–10)
 Visual analogue scale of pulmonary damage 0 (0–8)
 Visual analogue scale of cardiovascular damage 0 (0–10)
 Visual analogue scale of vascular damage 0 (0–5)
 Visual analogue scale of endocrine damage 0 (0–10)
 Visual analogue scale of ocular damage 0 (0–10)
 Visual analogue scale of infection damage 0 (0–10)
 Visual analogue scale of malignancy damage 0 (0–5)
 Visual analogue scale of other damage 0 (0–10)
 Visual analogue scale of global damage 5 (0–10)
 Damage extension 0.04 (0–0.52)
 Damage severity 0.045 (0–0.5)
 Extended damage 0 (0–10)
 Health assessment questionnaire (HAQ) 0 (0–3)
Treatment
 Prednisone dose (mg/day) 15 (2–100)
 Methotrexate dose (mg/week) 20 (2.5–30)
 Azathioprine dose (mg/day) 75 (50–175)
 Mycophenolate mofetil dose (g/day) 1.5 (0.5–2.5)
 Anti-malarial dose (mg/day) 200 (150–400)
Laboratory and cardio-pulmonary features
 Creatine phosphokinase (U/L) 170 (10–13,325)
 Aldolase (U/L) 8.7 (6.2–131)
 Alanine aminotransferase (U/L) 31 (5–435)
 Aspartate aminotransferase (U/L) 30 (10–1441)
 Lactate dehydrogenase (U/L) 226 (45–1243)
 C-reactive protein (mg/dL) 0.26 (0.01–13.3)
 Erythrocyte sedimentation rate (mm/Hr) 8 (1–56)
 Percentage of predicted forced vital capacity 81 (45–108)
 Pulmonary artery systolic pressure (mmHg) 32 (20–62)
 Percentage of left ventricle ejection fraction 61 (37–76)
 Tricuspid annular plane systolic excursion (TAPSE) 20 (11–26)